Bio-Techne Corporation Set to Reveal Q2 Earnings – Analysts Predict Steady Growth
Company Overview and Earnings Forecast
Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. With a market cap of $12 billion, Bio-Techne operates across Protein Sciences, as well as Diagnostics and Genomics segments.
The biotechnology company plans to announce its second-quarter results on Thursday, Feb. 6. Analysts project that Bio-Techne will report a non-GAAP profit of $0.33 per share, matching the same figure from the previous year. Over the last four quarters, the company has met or exceeded Wall Street’s bottom-line expectations three times, although it did fall short once. In its most recent reported quarter, adjusted EPS increased 5.7% year-over-year to $0.37, surpassing analysts’ estimates by 8.8%.
Looking Ahead: Fiscal Projections
For fiscal 2025, Bio-Techne is expected to deliver an adjusted EPS of $1.68, reflecting a 7% increase from $1.57 in fiscal 2024. By fiscal 2026, analysts anticipate a significant earnings boost of 20.2% year-over-year, projecting EPS to reach $2.02 per share.
Stock Performance Comparison
Over the past 52 weeks, TECH stock prices have risen by 8.6%, which is significantly lower than the S&P 500 Index’s increase of 26.5%. However, it has outperformed the Healthcare Select Sector SPDR Fund’s (XLV) modest gains during the same period.
Q1 Results and Analyst Sentiment
Bio-Techne experienced a substantial 7.5% jump in stock price following the release of its Q1 results on Oct. 30. The company reported a strong 4.5% year-over-year growth in net sales, totaling $289.5 million, surpassing Wall Street’s expectations by 3.1%. This growth was primarily driven by robust performance in the Diagnostics & Spatial Biology (DSS) segment, which recorded an impressive 14.3% year-over-year revenue increase to $83.2 million. Furthermore, Bio-Techne’s earnings exceeded analysts’ predictions by a significant margin.
Overall, analysts maintain a positive outlook for the stock. Bio-Techne currently holds a consensus “Strong Buy” rating. Among the 13 analysts covering the stock, 10 recommend a “Strong Buy,” while three suggest a “Hold.” The mean price target of $85 indicates a potential 12.1% upside from current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
